SK Biopharm Reports Operating Loss of 57.8 Billion KRW in Q2
[Asia Economy Reporter Park Jihwan] SK Biopharm announced on the 14th that its operating loss for the second quarter of this year amounted to 57.8 billion KRW.
The operating loss improved by 11.2% due to a decrease in selling and administrative expenses. The operating loss in the first quarter of this year was 65.1 billion KRW.
Hot Picks Today
![About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051416263163580_1778743590.jpg)
About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Envious of Korean Daily Life"...Foreign Tourists Line Up in Central Myeongdong from Early Morning [Reportage]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
On a consolidated basis, sales amounted to 2.1 billion KRW, down 47.4% compared to the previous quarter.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
